Overview: Prostate-Specific Antigen Immunohistochemistry TestIntroduction: The Prostate-Specific Antigen Immunohistochemistry Test detects PSA to diagnose prostate cancer, causing urinary issues or pain. Following 2023 NCCN guidelines, it uses immunohistochemistry for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected prostate cancer.
Other Names: PSA IHC Assay, Prostate Cancer IHC Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: PSA testing began in the 1980s with prostate cancer research. Immunohistochemistry-based methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects PSA to diagnose prostate cancer, guides treatment, and evaluates patients with urinary issues or pain.
Test Parameters: 1. Prostate Specific Antigen
Pretest Condition: No fasting required. Collect tissue via prostate biopsy or surgery. Report history of urinary issues, pelvic pain, or prostate enlargement.
Specimen: 0.5-2 cma³ tissue (FFPE). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document urinary issues, pelvic pain, erectile dysfunction, or family history of prostate cancer. Include current medications, especially hormone therapies.
Consent: Written consent required, detailing the tests purpose, cancer implications, and risks of biopsy or surgery.
Procedural Considerations: Uses immunohistochemistry to detect PSA in prostate tissue. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for prostate cancer diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or processing can affect results. Low tissue quality may reduce staining accuracy.
Clinical Significance: Positive PSA staining confirms prostate cancer, guiding surgery, radiation, or hormone therapy. Negative staining may require further marker testing.
Specialist Consultation: Consult a urologist or oncologist for result interpretation and treatment planning.
Additional Supporting Tests: Serum PSA levels, AMACR IHC, or prostate MRI to confirm prostate cancer diagnosis.
Test Limitations: Not specific to prostate cancer; benign prostatic hyperplasia may express PSA. Clinical correlation is needed.
References: NCCN Prostate Cancer Guidelines, 2023; American Journal of Surgical Pathology, Epstein JI, 2022.
